{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:59:21Z","timestamp":1790395161738,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1053\/j.ackd.2019.09.002","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T19:14:57Z","timestamp":1583435697000},"page":"72-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Association of Mesalamine With Kidney Disease"],"prefix":"10.1053","volume":"27","author":[{"given":"Avinash","family":"Adiga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2019.09.002_bib1","series-title":"MESALAMINE - mesalamine tablet, delayed release","year":"2019"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.002_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00296-011-2179-1","article-title":"Effects of dialysis on the pharmacokinetics of salazosulfapyridine","volume":"33","author":"Inami","year":"2013","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1053\/j.ackd.2019.09.002_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM197309062891001","article-title":"Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype","volume":"289","author":"Das","year":"1973","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.002_bib4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.51.4.536","article-title":"Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines","volume":"51","author":"Ransford","year":"2002","journal-title":"Gut"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.002_bib5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/ndt\/15.5.736-a","article-title":"Clearance of an oral delayed-release mesalazine preparation (Salofalk) by haemodialysis\u2014pharmacokinetic profile of mesalazine related to the effects of dialysis","volume":"15","author":"Verzijl","year":"2000","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2019.09.002_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/00365529009091911","article-title":"Mesalazine: an overview of key preclinical studies","volume":"172","author":"Bilyard","year":"1990","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.002_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ibd.20099","article-title":"5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review","volume":"13","author":"Gisbert","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1053\/j.ackd.2019.09.002_bib8","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/ndt\/gfp277","article-title":"A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis","volume":"24","author":"Augusto","year":"2009","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.002_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/SGA.0000000000000026","article-title":"Mesalamine-induced nephrotoxicity in the treatment of Crohn disease: a case study","volume":"37","author":"Chen","year":"2014","journal-title":"Gastroenterol Nurs"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.002_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2215\/CJN.04660513","article-title":"The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease","volume":"9","author":"Ambruzs","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.002_bib11","first-page":"461","article-title":"Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease","volume":"8","author":"Kreisel","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.002_bib12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ecco-jcc\/jjv138","article-title":"Renal involvement in inflammatory bowel diseases","volume":"10","author":"Corica","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1053\/j.ackd.2019.09.002_bib13","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1053\/j.gastro.2004.03.016","article-title":"5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study","volume":"126","author":"Van Staa","year":"2004","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1053\/j.ackd.2019.09.002_bib14","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1136\/gut.52.10.1530","article-title":"Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines","volume":"52","author":"Logan","year":"2003","journal-title":"Gut"},{"issue":"9","key":"10.1053\/j.ackd.2019.09.002_bib15","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/ndt\/12.9.1839","article-title":"5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?","volume":"12","author":"De Broe","year":"1997","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.002_bib16","first-page":"265","article-title":"Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease","volume":"49","author":"Calvi\u00f1o","year":"1998","journal-title":"Clin Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.002_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/ecco-jcc\/jjv219","article-title":"Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease","volume":"10","author":"Heap","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.002_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1442-200X.2012.03745.x","article-title":"Pediatric case of mesalazine-induced interstitial nephritis with literature review","volume":"55","author":"Co","year":"2013","journal-title":"Pediatr Int"},{"issue":"6","key":"10.1053\/j.ackd.2019.09.002_bib19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gut.40.6.761","article-title":"Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate","volume":"40","author":"Schreiber","year":"1997","journal-title":"Gut"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.002_bib20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000201459","article-title":"5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease","volume":"58","author":"H\u00e4mling","year":"1997","journal-title":"Digestion"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.002_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/2231-0770.94804","article-title":"Nephrotic syndrome after treatment of Crohn's disease with mesalamine: case report and literature review","volume":"2","author":"Firwana","year":"2012","journal-title":"Avicenna J Med"},{"issue":"30","key":"10.1053\/j.ackd.2019.09.002_bib22","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.3748\/wjg.v12.i30.4819","article-title":"Extraintestinal manifestations and complications in inflammatory bowel diseases","volume":"12","author":"Rothfuss","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.002_bib23","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/gast.2002.36613","article-title":"Primary chronic interstitial nephritis in Crohn's disease","volume":"123","author":"Izzedine","year":"2002","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.002_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/BF02048269","article-title":"Comparison of relative risks of urinary stone formation after surgery for ulcerative colitis: conventional ileostomy vs. J-pouch. A comparative study","volume":"39","author":"Christie","year":"1996","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.002_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ndt\/gfv005","article-title":"Enteric hyperoxaluria: an important cause of end-stage kidney disease","volume":"31","author":"Nazzal","year":"2016","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"10.1053\/j.ackd.2019.09.002_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/j.ackd.2012.07.014","article-title":"Uric acid stones and hyperuricosuria","volume":"19","author":"Mehta","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10.1053\/j.ackd.2019.09.002_bib27","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1053\/j.ajkd.2017.05.013","article-title":"Sulfasalazine-induced crystalluria causing\u00a0severe acute kidney injury","volume":"70","author":"Durando","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.002_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00005792-199209000-00001","article-title":"Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients","volume":"71","author":"Greenstein","year":"1992","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.002_bib29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00004836-200102000-00019","article-title":"Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine","volume":"32","author":"Margetts","year":"2001","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.002_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5858\/arpa.2012-0224-CR","article-title":"Granulomatous interstitial nephritis as a manifestation of Crohn disease","volume":"138","author":"Colvin","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.2000.00683.x","article-title":"Review article: Interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease","volume":"14","author":"Corrigan","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.002_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1155\/2009\/501345","article-title":"Renal effects of long-term treatment\u00a0with 5-aminosalicylic acid","volume":"23","author":"Patel","year":"2009","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"10.1053\/j.ackd.2019.09.002_bib33","first-page":"437","article-title":"5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells","volume":"4","author":"Kennedy","year":"1999","journal-title":"Int J Mol Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.002_bib34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4103\/0253-7613.178840","article-title":"The effect of 5-aminosalicylic acid on renal ischemia-reperfusion injury in rats","volume":"48","author":"Banaei","year":"2016","journal-title":"Indian J Pharmacol"},{"issue":"2","key":"10.1053\/j.ackd.2019.09.002_bib35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.15537\/smj.2017.2.16049","article-title":"Antioxidant effect of vitamin E and 5-aminosalicylic acid on acrylamide induced kidney injury in rats","volume":"38","author":"Rajeh","year":"2017","journal-title":"Saudi Med J"},{"issue":"3","key":"10.1053\/j.ackd.2019.09.002_bib36","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1053\/j.ackd.2019.09.002_bib37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of\u00a0Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"issue":"5","key":"10.1053\/j.ackd.2019.09.002_bib38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management\u00a0of inflammatory bowel disease in adults","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:02:08Z","timestamp":1761548528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559519301661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1548559519301661"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.09.002","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Association of Mesalamine With Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}